MYC and B-cell non-Hodgkin lymphoma: Mechanistic experiments linked this effect to the MYC-EGR1 transcription factor complex, and suggested that MYC overexpression represents a redox-sensitive vulnerability that can be therapeutically targeted with antioxidants in B-cell lymphoma (Yao et al, 2023).